For most patients with T2D and DKD, metformin and SGLT2 inhibitors are recommended as the first-line pharmacologic treatment with eGFR is above 30 mL/min/1.73 m2 [159]. This evidence concerns the gene SLC5A2 and diabetic kidney disease.